A Multi-centre, Randomized, Double-blind, Placebo Controlled, Two-period, Crossover Proof-of-concept Study in Male Patients With Fragile X Syndrome to Assess the Efficacy, Safety and Tolerability of Multiple Oral Doses of AFQ056
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Mavoglurant (Primary)
- Indications Behavioural symptoms; Fragile X syndrome
- Focus Therapeutic Use
- 12 Nov 2012 New trial record